Fundies. English
Segment disclosures
Company overviewWATERS CORP /DE/
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
30 dimension combinations 167 retained observations 6 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Material Reconciling Items · Waters Advanced Diagnostics
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 521000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 870000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 349000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 62000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 115000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 53000000 | USD | 20260512 | Open filing evidence |
Material Reconciling Items · Waters Analytical And Materials Sciences
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 756000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 1442000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 686000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 709000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 1318000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 609000000 | USD | 20260512 | Open filing evidence |
Material Reconciling Items · Waters Biosciences
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:MaterialReconcilingItemsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 368000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 600000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 232000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 521000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 870000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 349000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 62000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 115000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 53000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · CN
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=country:CN| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 40000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 66000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 26000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 10000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 20000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 10000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · US
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 195000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 316000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 121000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 19000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 35000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 16000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · Americas
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 242000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 393000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 151000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 25000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 44000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 19000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · Asia Pacific
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 95000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 161000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 66000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 14000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 29000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 15000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · European Union
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=us-gaap:EuropeanUnionMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 184000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 316000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 132000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 23000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 42000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 19000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · Americas Other
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=wat:AmericasOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 47000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 77000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 30000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 6000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 9000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 3000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Advanced Diagnostics · Asia Other
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAdvancedDiagnosticsMember;srt:StatementGeographicalAxis=wat:AsiaOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 55000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 95000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 40000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 4000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 9000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 5000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 756000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 1442000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 686000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 709000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 1318000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 609000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · CN
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=country:CN| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 118000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 218000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 100000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 107000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 188000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 81000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · US
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 226000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 430000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 204000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 210000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 410000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 200000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · Americas
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 273000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 519000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 246000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 255000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 492000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 237000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · Asia Pacific
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 274000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 507000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 233000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 252000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 458000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 206000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · European Union
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=us-gaap:EuropeanUnionMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 209000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 416000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 207000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 202000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 368000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 166000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · Americas Other
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=wat:AmericasOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 47000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 89000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 42000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 45000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 82000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 37000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Analytical And Materials Sciences · Asia Other
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersAnalyticalAndMaterialsSciencesMember;srt:StatementGeographicalAxis=wat:AsiaOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 156000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 289000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 133000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 145000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 270000000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 125000000 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 368000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 600000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 232000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences · CN
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=country:CN| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 48000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 75000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 27000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences · US
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 149000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 239000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 90000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences · Americas
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=srt:AmericasMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 175000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 283000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 108000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences · Asia Pacific
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 81000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 132000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 51000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences · European Union
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=us-gaap:EuropeanUnionMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 112000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 185000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 73000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
Operating Segments · Waters Biosciences · Americas Other
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=wat:AmericasOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 26000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 44000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 18000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Operating Segments · Waters Biosciences · Asia Other
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=wat:WatersBiosciencesMember;srt:StatementGeographicalAxis=wat:AsiaOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-05 – 2026-07-04 | 33000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-07-04 | 57000000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-04-04 | 24000000 | USD | 20260512 | Open filing evidence |
| 2025-03-30 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-28 | 0 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-29 | 0 | USD | 20260512 | Open filing evidence |
Customer Concentration Risk · Governmental And Academic Segment
Concentration Risk By Type · Statement Business Segments
Source dimensions
us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=wat:GovernmentalAndAcademicSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-01-01 – 2018-03-31 | 63012000 | USD | 20180504 | Open filing evidence |
| 2017-01-01 – 2017-04-01 | 56856000 | USD | 20180504 | Open filing evidence |
Customer Concentration Risk · Industrial Segment
Concentration Risk By Type · Statement Business Segments
Source dimensions
us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=wat:IndustrialSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-01-01 – 2018-03-31 | 162330000 | USD | 20180504 | Open filing evidence |
| 2017-01-01 – 2017-04-01 | 161303000 | USD | 20180504 | Open filing evidence |
Customer Concentration Risk · Pharmaceutical Segment
Concentration Risk By Type · Statement Business Segments
Source dimensions
us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=wat:PharmaceuticalSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-01-01 – 2018-03-31 | 305328000 | USD | 20180504 | Open filing evidence |
| 2017-01-01 – 2017-04-01 | 279810000 | USD | 20180504 | Open filing evidence |